Status Unknown
Randomized, Double-Blind, Parallel Group, Placebo Controlled, Tolerability, Safety and Pilot Efficacy Study of CPI-1189 in HIV Infected Individuals With Cognitive and Motor Impairment
Led by Centaur Pharmaceuticals · Updated on 2005-06-24
60
Participants Needed
6
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.
CONDITIONS
Brief Title
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
Who Can Participate
Eligibility Criteria
Inclusion Criteria
You may be eligible for this study if you:
- Are HIV-positive.
- Are at least 18 years old.
- Have symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control.
- Have been on stable anti-HIV drug therapy for the past 6 weeks (if you are taking anti-HIV drugs).
Exclusion Criteria
You will not be eligible for this study if you:
- Have certain serious medical conditions, such as a mental disorder or an opportunistic (AIDS-related) infection.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here